The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.PersonalizedMedicineCoalition.org.
EMC Corporation is a global leader in enabling businesses to transform their operations and deliver IT as a service. Through innovative products and services, EMC accelerates the journey to cloud computing, helping IT departments to store, manage, protect and analyze information in a more agile, trusted and cost-efficient way. http://www.emc.com/about/index.htm
Big Science Media publishes Genome magazine (April 2014 launch), which covers the personalized medicine stories of today and the breakthroughs of tomorrow, so patients have the information they need to effectively manage their health. Personalized medicine is changing the way health care is delivered, but a crucial part of the process – patient education – is just beginning. Genome magazine acts as an information bridge, bringing relevant insight and knowledge to patients, family and caregivers, enabling people with chronic and life-altering diseases to live better, longer. www.cancercenter.com.
Since 1993, BioCentury Publications, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. http://www.biocentury.com/
The SCGPM was established in 2009 from within the department of Genetics at the Stanford Medical School. The SCGPM now involves more than 60 faculty from 13 departments with diverse research interests spanning basic science to clinical medicine. http://scgpm.stanford.edu/.
MediSapiens offers a wide selection of software and products for biological research. The Company has a successful track record of creating customized bioinformatic software solutions to various organizations worldwide; ranging from comprehensive data management system for Bayer HealthCare to full sample and data processing system to MyDogDNA, an animal DNA testing service. http://medisapiens.com/
Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the universal adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.
OMI is developing novel biomarkers based on clinical and genomic data and is using information generated from multiple sources to develop new treatments for neuro-immune and other diseases. http://openmedicineinstitute.org/
Trovagene is setting out to change the way cancer is treated through a simple urine sample and the analysis of cell-free DNA from that sample, along with associated oncogene mutations. This can ultimately lead to more effective disease monitoring, improved treatment outcomes, and earlier detection of recurrent disease in cancer survivors. http://www.trovagene.com/
QIAGEN Bioinformatics is powered by CLC bio, Ingenuity, and BIOBASE. We offer bioinformatics software tools for next generation sequencing (NGS) data analysis and interpretation. Our solutions are designed to be universal, so you can mix and match the technologies best suited to your needs. http://www.qiagen.com/
Macrogen specializes in a wide variety of DNA / RNAsequencing applications, and offers both sequencing and data analysis services. http://www.macrogenlab.com/
Omicia is advancing next-gen sequencing (NGS) in the clinic with software solutions for clinical testing, disease research, and drug development. Our Opal™ interpretation and reporting platform enables accurate, rapid analysis of variants to identify the genetic cause of hereditary disease and somatic cancer. For more information, visit http://www.omicia.com/ and follow us on Twitter @omicia.
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community. http://www.broadinstitute.org/
Oracle is the leading strategic software solutions provider to the health sciences industry. Oracle's comprehensive industry solutions include clinical trial management/analysis, electronic data capture, adverse event reporting / pharmacovigilance, and healthcare interoperability. Oracle partners with health sciences industry leaders to prevent and cure disease, enhance quality of life, and accelerate insights for better health. http://www.oracle.com/us/industries/health-sciences/overview/index.html
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient. www.molecularhealth.com
Helomics™ is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. We are dedicated to improving patient outcomes by utilizing a proprietary set of laboratory platforms and our Product Science as a Service commercialization model to allow physicians to characterize malignant tumors. Our novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer. http://www.helomics.com/#about_us
Novellus Dx is the leader in Precision Prognostic Cancer Analysis ™, and through its unique proprietary diagnostic platform, charts the full hierarchy of mutations that drive a cancer’s progression. NovellusDX’s Prognostic Cancer Analysis System can assess the behavior of mutations and their response to targeted drugs for every patient individually. In addition, the Prognostic Cancer Analysis System helps bio-pharma companies identify expanded subgroups of cancer patients who are likely to respond to existing therapies and enables more focused and efficient trials and isolate new mutations to target. http://novellusdx.com/wp/
NanoString® Technologies develops innovative products that unlock valuable and clinically actionable genomic information from small amounts of tissue. http://www.nanostring.com/
GenoLogics is a leading provider of laboratory information management system (LIMS) software designed for use with genomics and mass spec technologies in regulated and research labs. Clarity LIMS offers quick implementation, an intuitive interface and features that makes it a valuable investment for labs utilizing NGS and other -omics technologies. https://www.genologics.com/
Appistry CloudDx provides cost-effective access to established, laboratory developed tests so that clinically relevant genomics-based information can be usable by any physician, anywhere. Appistry also empowers researchers by providing world-class bioinformatics tools, cloud services, and software that streamline the analysis of next-generation sequencing data and provide easy scale for moving research-developed pipelines into production. http://www.appistry.com/
DNAnexus is powering the genomics revolution with an enterprise-level solution that combines cloud computing with advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish DNAnexus at the center of a growing ecosystem of scientific and clinical research, and diagnostic efforts in personalized medicine. https://dnanexus.com
Applied Microarrays (“AMI”) is the leading contract producer of point-of-care multiplex diagnostic devices on semiconductor and glass/plastic hybrid platforms. AMI manages all aspects of the supply chain from wafer production, circuit board assembly, bio-content application on detection microarrays, and microfluidic cartridge assembly. Additionally AMI manufactures multiplex diagnostic arrays on multi-array slides and microtiter plates, for high throughput CLIA lab applications such as infectious disease, autoimmune disease and allergy/food intolerance testing. The company acquired GE Healthcare’s microarray assets and facility in 2007, is ISO9001/13485 certified, and operates from a world class former Motorola cleanroom in Tempe Arizona, and from 2015 in Singapore. http://www.appliedmicroarrays.com/
HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit, http://www.humanlongevity.com
At Data4Cure we believe it is time to move from individual genomic variants to a comprehensive systems view of health and disease. We harness big data using a multidimensional map of human biology to help researchers and clinicians improve patient care. We develop the Biomedical Intelligence™ platform for personalized systems medicine. More at http://www.data4cure.com
DxEconomix helps IVD companies bring novel diagnostic and technology solutions to market in the era of healthcare reform. We do this by assessing and quantifying clinical and economic benefits within the context of the entire care pathway, not just their impact on laboratory or other silo budgets. We use this evidence to engage payors and achieve value based pricing for IVD companies across markets in US, Canada and Europe. http://www.dxeconomix.com
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-cell and B-cell Receptors. http://www.adaptivebiotech.com/
Biosearch Technologies, Inc. is an ISO 13485:2003 certified and cGMP compliant manufacturer of oligonucleotides for molecular diagnostics and real-time qPCR applications in the pharmaceutical, biotechnology, public health, biodefense, ag/bio, environmental and food testing, and in vitro diagnostic markets. Biosearch conforms to all applicable GMP requirements per 21 CFR Part 820. For more info, visit: www.biosearchtech.com.
Meso Scale Discovery develops and markets solutions for multiplex biological assays for biomarkers, cytokines and phosphoproteins. http://www.mesoscale.com/
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer to help physicians in matching them with relevant targeted therapies and clinical trials. http://www.foundationmedicine.com/
Cancer Treatment Centers of America (CTCA) is a national network of hospitals providing a comprehensive, fully integrated approach to cancer treatment. CTCA serves patients with complex cancer at facilities located suburban Atlanta, Chicago, Philadelphia, suburban Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowered Care®, CTCA provides patients with information about cancer and their treatment options, so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
Thomson Reuters provides the knowledge, tools and expertise to support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly-changing pharmaceutical and chemical markets, and make the best decisions for your business. http://lifesciences.thomsonreuters.com/
IDT specializes in DNA synthesis, gene construction, antisense oligos, molecular beacons and a variety of molecular biology products. http://www.idtdna.com/site
Journal of Precision Medicine will cover a comprehensive timeline from discovery to diagnosis and discuss the confluence of genomic technologies and diagnostic tools that will play their part in detecting disease and offer insights into therapeutic solutions for a range of hitherto unmet medical needs. Website: http://www.thejournalofprecisionmedicine.com/